Q4 2025 PI Industries Ltd Earnings Call Transcript
Key Points
- PI Industries Ltd (BOM:523642) reported a 6% growth in revenue and a 17% growth in EBIT for the year, indicating strong financial performance.
- The company has successfully commercialized 15 molecules over the past two years, with a robust pipeline focusing on ag chem molecules.
- Domestic branded revenue grew by 21% year-on-year, supported by a strong Rabi season and increased acreages in wheat, rice, and pulses.
- The company is expanding its addressable market in innovative products in agriculture and pharmaceuticals, aiming to become a global technology platform leader.
- PI Industries Ltd (BOM:523642) has been recognized for its ESG efforts, retaining its listing in the S&P Global Sustainability Yearbook for the second time in 2025.
- Price realization remains under pressure due to global oversupplies, increasing generic competition, and declining raw material costs.
- The consolidated financials were marginally lower due to development spend in the pharmaceutical business.
- The trade working capital days increased to 73 days, indicating potential inefficiencies in managing receivables and inventory.
- The company's pharma business is still incurring losses, with an EBITDA loss of INR180-190 crores for the full year.
- The effective tax rate increased to 22.5% from 11.2% last year, impacting the net profit margin.
Ladies and gentlemen, good day, and welcome to PI Industries Limited Q4 FY25 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Nishid Solanki from CDR India. Thank you, and over to you, Mr. Solanki.
Good afternoon, everyone, and thank you for joining us on PI Industries Q4 FY25 Earnings Conference Call. Today, we are joined by senior members of the management team, including Mr. Mayank Singhal, Executive Vice Chairman and Managing Director; Mr. Rajnish Sarna, Joint Managing Director; Mr. Sanjay Agarwal, Group Chief Financial Officer; Dr. Atul Gupta, CEO, Exports; Mr. Prashant Hegde, CEO of Domestic Brands; and Dr. Ramesh Rama Subramanian, Global CEO, PI Health Sciences. We will begin the call with key perspectives from Mr. Singhal. Following that, Mr. Agarwal will share his views on the financial performance. Thereafter, the forum will be open for question-and-answer session.
Before we begin, I would like to underline
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
